Bio-Techne (TECH) GC sees RSUs vest, others forfeited on equity awards
Rhea-AI Filing Summary
BIO-TECHNE Corp (TECH) reported that officer Shane Bohnen, SVP – General Counsel, had multiple equity award events on 2026-08-15. Awards of restricted stock units and performance restricted stock units were converted into 4,350 shares of Common Stock, with 1,343 shares delivered or withheld for payment of exercise price or tax liability. The Board authorized discretionary vesting of 807 performance stock options and 300 performance RSUs, while the remaining related performance options and performance RSUs were forfeited and disposed to the issuer. Bohnen continues to hold several stock option grants on BIO-TECHNE Common Stock with exercise prices ranging from $53.60 to $120.46 and expiration dates between 2027 and 2035, as well as unvested performance RSUs. The transactions were not reported as made under a Rule 10b5-1 trading plan.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 3,007 shares
Net Buy
17 txns
Insider
Bohnen Shane
Role
SVP - General Counsel
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units F3, F5 | 49 | $0.00 | $0.00 |
| Disposition | Performance Stock Option (Right to Buy) F6 | 12,117 | $0.00 | $0.00 |
| Exercise | Performance Restricted Stock Units F3, F7 | 300 | $0.00 | $0.00 |
| Disposition | Performance Restricted Stock Units F3, F7 | 4,502 | $0.00 | $0.00 |
| Exercise | Restricted Stock Units F3, F9 | 1,669 | $0.00 | $0.00 |
| Exercise | Restricted Stock Units F3, F12 | 2,332 | $0.00 | $0.00 |
| Exercise | Common Stock | 4,350 | $0.00 | $0.00 |
| Exercise Price or Tax Liability | Common Stock | 1,343 | $72.40 | $97K |
| holding | Stock Option (Right to Buy) F1 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F1 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F1 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F2 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F4 | -- | -- | -- |
| holding | Performance Restricted Stock Units F3, F8 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F10 | -- | -- | -- |
| holding | Performance Restricted Stock Units F3, F11 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F13 | -- | -- | -- |
Holdings After Transaction:
Restricted Stock Units — 6,333 shares (Direct);
Performance Stock Option (Right to Buy) — 807 shares (Direct);
Performance Restricted Stock Units — 24,004 shares (Direct);
Common Stock — 10,360 shares (Direct);
Stock Option (Right to Buy) — 67,527 shares (Direct)
Footnotes (13)
- F1. Fully exercisable.
- F2. Options to purchase 982 shares vest on each of 4/3/2024, 4/3/2025, 4/3/2026 and 4/3/2027.
- F3. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
- F4. Options to purchase 4,076 shares vest on 8/15/2024 and 8/15/2026, and options to purchase 4,075 shares vest on 8/15/2025 and 8/15/2027.
- F5. 49 restricted stock units vest on 8/15/2026.
- F6. On 8/15/2026, the Board of Directors authorized discretionary vesting for 807 performance options. The remainder of the performance options were forfeited.
- F7. On 8/15/2026, the Board of Directors authorized discretionary vesting for 300 performance RSUs. The remainder of the performance RSUs were forfeited.
- F8. Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- F9. 1,669 restricted stock units vest on each of 8/15/2026 and 8/15/2027.
- F10. Options to purchase 3,372 shares vest on each of 8/15/2025, 8/15/2026, 8/15/2027 and 8/15/2028.
- F11. Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- F12. 2,332 restricted stock units vest on each of 8/15/2026, 8/15/2027 and 8/15/2028.
- F13. Options to purchase 5,966 shares vest on each of 8/15/2026 and 8/15/2027, and options to purchase 5,965 shares vest on 8/15/2028.
Key Figures
Common shares acquired via award conversion: 4,350 shares
Shares delivered/withheld for exercise price or tax: 1,343 shares at $72.40 per share
Performance options disposed to issuer: 12,117 options at $84.61 exercise price
+5 more
8 metrics
Common shares acquired via award conversion
4,350 shares
Common Stock acquired on 2026-08-15 from exercises/conversions (code M, acquired_disposed_code A)
Shares delivered/withheld for exercise price or tax
1,343 shares at $72.40 per share
Common Stock, code F, payment of exercise price or tax liability
Performance options disposed to issuer
12,117 options at $84.61 exercise price
Performance Stock Option (Right to Buy) disposed to issuer on 2026-08-15
Discretionary vesting performance options
807 options
Board authorized discretionary vesting of 807 performance options on 8/15/2026
Discretionary vesting performance RSUs
300 RSUs
Board authorized discretionary vesting of 300 performance RSUs on 8/15/2026
Option exercise price range
$53.60 to $120.46 per share
Exercise prices for remaining Stock Option (Right to Buy) positions
Largest remaining option grant underlying shares
17,897 shares
Stock Option (Right to Buy) at $53.60 exercise price expiring 2035-08-15
Remaining performance RSUs (grant example)
13,992 underlying shares
Performance Restricted Stock Units vesting based on performance goals by 8/15/2028
Key Terms
Performance Restricted Stock Units, Performance stock options, Disposition to issuer, Exercise price, +2 more
6 terms
Performance Restricted Stock Units financial
"Performance Restricted Stock Units vest in full or in part on 8/15/2028"
Performance restricted stock units (PRSUs) are promises to deliver company shares to employees or executives only if the business meets specific performance targets and any time-based holding rules. Think of them as a bonus that converts into stock only after set goals are reached, so investors watch PRSUs for two reasons: they can dilute existing shares if paid out, and they signal how closely management’s pay is tied to company performance.
Performance stock options financial
"the Board of Directors authorized discretionary vesting for 807 performance options"
Disposition to issuer financial
"Performance Stock Option (Right to Buy) listed with transaction code D as disposition to issuer"
Exercise price financial
"Stock Option (Right to Buy) with an exercise price of 84.6100"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
Contingent right financial
"Each restricted stock unit represents a contingent right to receive one share"
Payment of exercise price or tax liability financial
"transaction code F denotes payment of exercise price or tax liability"
FAQ
What did TECH officer Shane Bohnen report in this Form 4 for BIO-TECHNE Corp (TECH)?
Shane Bohnen reported conversions of equity awards into 4,350 shares of BIO-TECHNE Common Stock, forfeitures of certain performance-based awards, and continuing holdings of stock options and performance RSUs with various exercise prices and expirations.
What performance awards were affected for Shane Bohnen at BIO-TECHNE (TECH)?
The Board authorized discretionary vesting of 807 performance stock options and 300 performance RSUs for Shane Bohnen. According to the disclosure, the remaining related performance options and performance RSUs were forfeited and disposed to the issuer.
What stock options does Shane Bohnen still hold in BIO-TECHNE Corp (TECH)?
Bohnen continues to hold stock options on BIO-TECHNE Common Stock with exercise prices of $66.97, $73.76, $74.91, $84.61, $94.52, $120.46, and $53.60, covering underlying shares noted as outstanding and expiring between 2027 and 2035.
Were Shane Bohnen’s BIO-TECHNE (TECH) transactions under a Rule 10b5-1 trading plan?
The filing’s Rule 10b5-1 checkbox is marked false, indicating these transactions were not reported as effected under a Rule 10b5-1 or similar pre-arranged trading plan, based on the company’s disclosure.
How were restricted stock units treated in Shane Bohnen’s BIO-TECHNE (TECH) Form 4?
Restricted stock units and performance RSUs each represent a contingent right to receive one share of BIO-TECHNE common stock. Some RSUs and performance RSUs vested and converted into common shares, while others were forfeited and disposed to the issuer.
AI-generated analysis. How Rhea-AI works. Not financial advice.
